🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

545 results for “B.” Clear

  1. ALN-AGT01 RVR

    Alnylam Netherlands B.V.

    Hypertension

    phase 2 small molecule active

    1 trial

  2. ALN-CC5

    Alnylam Netherlands B.V.

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 2 small molecule completed

    1 trial

  3. ALN-KHK

    Alnylam Netherlands B.V.

    Type 2 Diabetes Mellitus (T2DM)

    phase 2 small molecule terminated

    1 trial

  4. ALN-RSV01

    Alnylam Netherlands B.V.

    Respiratory Syncytial Virus Infections

    phase 2 small molecule completed

    3 trials

  5. ALN-TTR02 (patisiran) administered by intravenous (IV) infusion

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 2 small molecule completed

    1 trial

  6. ALN-TTRSC (revusiran) for subcutaneous administration

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 2 small molecule completed

    1 trial

  7. ALN-XDH

    Alnylam Netherlands B.V.

    Gout

    phase 2 small molecule terminated

    1 trial

  8. AMX0035

    Amylyx Pharmaceuticals EMEA B.V.

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  9. AMX0035

    Amylyx Pharmaceuticals EMEA B.V.

    ALS

    phase 2 small molecule active

    1 trial

  10. AMX0035

    Amylyx Pharmaceuticals EMEA B.V.

    Wolfram Syndrome

    phase 2 small molecule active

    1 trial

  11. APL-2

    Apellis Europe B.V.

    Warm Autoimmune Hemolytic Anemia

    phase 2 small molecule completed

    1 trial

  12. APL-2

    Apellis Europe B.V.

    IgA Nephropathy

    phase 2 small molecule completed

    1 trial

  13. APL-3007, pegcetacoplan (APL-2)

    Apellis Europe B.V.

    Geographic Atrophy Secondary to Age-related Macular Degeneration

    phase 2 small molecule active

    1 trial

  14. APL-9

    Apellis Europe B.V.

    COVID

    phase 2 small molecule completed

    1 trial

  15. ASTX727

    Taiho Pharma Netherlands B.V.

    Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) or solid tumors

    phase 2 small molecule active

    1 trial

  16. ASTX727, Venclyxto 50 mg film-coated tablets, Venclyxto 10 mg film-coated tablets, Venclyxto 100 mg film-coated tablets

    Taiho Pharma Netherlands B.V.

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  17. AZACITIDINE

    Blueprint Medicines (Netherlands) B.V.

    Advanced Systemic Mastocytosis

    phase 2 small molecule active

    1 trial

  18. AZD2014

    Samsung Bioepis NL B.V.

    Cancer of Stomach

    phase 2 small molecule terminated

    1 trial

  19. AZD9291

    Samsung Bioepis NL B.V.

    Non-Small Cell Lung Cancer With EGFR T790M Mutation

    phase 2 small molecule active

    1 trial

  20. Active drug: pimavanserin 17mg (2 strength tablets)

    Acadia Pharmaceuticals B.V.

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  21. Aldesleukin

    Iovance Biotherapeutics B.V.

    Bone Sarcoma

    phase 2 mab active

    1 trial

  22. An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients with primary mitochondrial disease

    Pharming Technologies B.V.

    Adult patients with primary mitochondrial disease

    phase 2 other active

    1 trial

  23. Autologous Tumor Infiltrating Lymphocytes MDA-TIL

    Iovance Biotherapeutics B.V.

    Malignant Solid Neoplasm

    phase 2 mab terminated

    1 trial

  24. Avapritinib, Avapritinib, Avapritinib

    Blueprint Medicines (Netherlands) B.V.

    Solid Tumors Dependent on KIT or PDGFRA Signaling

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources